In the latest of a string of issues Sarepta has faced, the CHMP said it was recommending against approval as the pivotal ...

After a tough few weeks for Sarepta Therapeutics Inc., the EMA dealt another blow on July 25, announcing it will not be ...

Elevidys scored an accelerated FDA approval in June 2023, quickly ranking as one of the world’s most expensive drugs with a list price of $3.2 million. As a gene therapy, the treatment was ...